The decision to bring forward the interim report is due to EQT VIII’s (“EQT VIII”), through Karo Intressenter AB, public offer for all shares in Karo Pharma Aktiebolag (“Karo Pharma”) (which was made public by EQT VIII earlier today, and which was recommended by the Board of Directors of Karo Pharma through a press release which also was made public earlier today).
In connection with the preparation of the offer, EQT VIII has carried out a limited confirmatory due diligence review of Karo Pharma, and through this review taken part of the interim report. The imbalance of information in the market is by the decision to bring the report forward corrected.
Furthermore, the Board of Directors of Karo Pharma wants to ensure that shareholders have all relevant and current information regarding the company’s financial development, well before the acceptance period expires on or around 10 December 2018.
Stockholm, 29 October 2018
Karo Pharma Aktiebolag
The Board of Directors
ABOUT KARO PHARMA
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.
The information was submitted for publication on October 29, 2018 at 08.00 CET. This press release is also available on www.newsroom.cision.com